DEF 14A: Singular Genomics Seeks Stockholder Approval for Reverse Stock Split and Director Elections

Singular Genomics Systems, Inc. is holding its 2024 Annual Meeting of Stockholders on May 29, 2024, to vote on director elections, ratification of the accounting firm, and a potential reverse stock split.

Summary

• Singular Genomics Systems, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 29, 2024.
• Stockholders will vote to elect three Class III directors (Andrew Spaventa, Marcia Eisenberg, Ph.D., and Michael Pellini, M.D.) to serve until the 2027 annual meeting.
• They will also vote to ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending December 31, 2024.
• A key proposal is to approve an amendment to the company's certificate of incorporation to allow for a reverse stock split at a ratio between 1-for-10 and 1-for-30, at the Board's discretion, before June 30, 2024.
• The record date for the Annual Meeting is April 1, 2024.
• The company is furnishing proxy materials online, with a Notice of Availability mailed to stockholders around April 18, 2024.
• As of February 29, 2024, there were 73,952,087 shares of common stock outstanding (excluding 23,530 unvested shares).

Sentiment

Score: 6

Explanation: The document is neutral, providing necessary information for stockholders to make informed decisions. The potential reverse stock split introduces uncertainty, but the company is taking proactive steps to address its stock price.

Positives

• Maintaining a listing on the Nasdaq Capital Market provides a broader market for the common stock and facilitates the use of the common stock in financing and other transactions.
• The Board believes that the current low per share market price of our common stock has a negative effect on the marketability of our existing shares and a Reverse Stock Split will result in a higher bid price for our common stock, which may help to alleviate some of these problems.

Negatives

• If the per share market price of the common stock does not increase in proportion to the reverse stock split ratio, then the value of the Company, as measured by our market capitalization, will be reduced.
• The Reverse Stock Split may be viewed negatively by the market and, consequently, could lead to a decrease in our overall market capitalization.
• The Reverse Stock Split may decrease, or may not increase, the liquidity of the common stock since there would be a reduced number of shares outstanding after the Reverse Stock Split.

Risks

• Failure to maintain a minimum bid price of $1.00 per share could result in delisting from the Nasdaq Capital Market.
• The reverse stock split may not increase the per share price of the common stock or maintain it long-term.
• Some investors may view the reverse stock split negatively, potentially impacting the market price.
• The reverse stock split may decrease, or may not increase, the liquidity of the common stock since there would be a reduced number of shares outstanding after the Reverse Stock Split.

Future Outlook

The company aims to maintain its Nasdaq Capital Market listing and increase the marketability of its shares through the potential reverse stock split.

Management Comments

• The Board believes that maintaining our listing on the Nasdaq Capital Market provides a broader market for the common stock and facilitates the use of the common stock in financing and other transactions.
• The Board also believes that the current low per share market price of our common stock has a negative effect on the marketability of our existing shares.

Industry Context

The company is addressing its stock price to maintain compliance with Nasdaq listing requirements, a common challenge for companies in the biotech sector.

Comparison to Industry Standards

• Many biotech companies facing similar stock price challenges have implemented reverse stock splits to regain compliance with exchange listing requirements.
• Comparable companies like Bionano Genomics (BNGO) have also used reverse stock splits to maintain their Nasdaq listing.
• The success of a reverse stock split in improving long-term stock performance varies significantly depending on the company's underlying fundamentals and market conditions.

Related Party Transactions

• The company is party to an amended and restated voting agreement with certain holders of our common stock, including Deerfield Private Design Fund IV, L.P., Domain Partners IX, L.P., LC Healthcare Fund I, L.P., and ARCH Venture Fund IX, L.P. and (ii) Mr. Spaventa, Dr. Glezer and Dr. Barker.
• The company has entered into indemnification agreements with each of its directors and executive officers.

Stakeholder Impact

• Shareholders will be directly impacted by the reverse stock split, if implemented, affecting the number of shares they own and potentially the stock price.
• Employees with stock options or RSUs will see adjustments to their awards to reflect the reverse stock split.
• The company's ability to raise capital and maintain its Nasdaq listing impacts all stakeholders, including employees, customers, and suppliers.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on May 29, 2024.
• The Board of Directors will decide whether to implement the reverse stock split, and at what ratio, by June 30, 2024, if approved by stockholders.
• The company will file a Form 8-K to announce the final voting results of the Annual Meeting.

Key Dates

Keywords

reverse stock split, annual meeting, proxy statement, director election, Ernst & Young, Singular Genomics, stockholders, governance, compensation